Abstract

Treatment resistance in alcohol use disorders (AUD) is a major problem for affected individuals and for society. In the search of new treatment options, few case studies using deep brain stimulation (DBS) of the nucleus accumbens have indicated positive effects in AUD. Here we report a double-blind randomized controlled trial comparing active DBS (“DBS-EARLY ON”) against sham stimulation (“DBS-LATE ON”) over 6 months in n = 12 AUD inpatients. This 6-month blind phase was followed by a 12-month unblinded period in which all patients received active DBS. Continuous abstinence (primary outcome), alcohol use, alcohol craving, depressiveness, anxiety, anhedonia and quality of life served as outcome parameters. The primary intention-to-treat analysis, comparing continuous abstinence between treatment groups, did not yield statistically significant results, most likely due to the restricted number of participants. In light of the resulting limited statistical power, there is the question of whether DBS effects on secondary outcomes can nonetheless be interpreted as indicative of an therapeutic effect. Analyses of secondary outcomes provide evidence for this, demonstrating a significantly higher proportion of abstinent days, lower alcohol craving and anhedonia in the DBS-EARLY ON group 6 months after randomization. Exploratory responder analyses indicated that patients with high baseline alcohol craving, depressiveness and anhedonia responded to DBS. The results of this first randomized controlled trial are suggestive of beneficial effects of DBS in treatment-resistant AUD and encourage a replication in larger samples.

Details

Title
Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial
Author
Bach, Patrick 1   VIAFID ORCID Logo  ; Luderer, Mathias 2   VIAFID ORCID Logo  ; Müller, Ulf Joachim 3 ; Jakobs, Martin 4   VIAFID ORCID Logo  ; Baldermann, Juan Carlos 5   VIAFID ORCID Logo  ; Voges, Jürgen 6 ; Kiening, Karl 4 ; Lux, Anke 7 ; Visser-Vandewalle, Veerle 8   VIAFID ORCID Logo  ; Klosterkötter, Joachim 9 ; Huys, Daniel 9 ; Sommer, Wolfgang 10 ; Weber, Tillmann 11 ; Bogerts, Bernhard 3 ; Kuhn, Jens 12 ; Mann, Karl 13 

 Heidelberg University, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); University of Heidelberg, Feuerlein Center on Translational Addiction Medicine (FCTS), Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373) 
 Goethe University, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 Otto-v.-Guericke University, Department of Psychiatry and Psychotherapy, University Hospital, Magdeburg, Germany (GRID:grid.5807.a) (ISNI:0000 0001 1018 4307) 
 University Hospital Heidelberg, Division for Stereotactic Neurosurgery, Department of Neurosurgery, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 University of Cologne, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 Otto-v.-Guericke University, Department of Stereotactic Neurosurgery, University Hospital, Magdeburg, Germany (GRID:grid.5807.a) (ISNI:0000 0001 1018 4307) 
 Magdeburg University, Institute of Biometry and Medical Informatics of the University Hospital Magdeburg, Magdeburg, Germany (GRID:grid.5807.a) (ISNI:0000 0001 1018 4307) 
 University Hospital Cologne, Department of Stereotactic Neurosurgery, Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X) 
 University of Cologne, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
10  Heidelberg University, Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373) 
11  AHG hospital Wilhelmsheim, Wilhelmsheim, Germany (GRID:grid.7700.0) 
12  University of Cologne, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); Johanniter Hospital, Department of Psychiatry, Psychotherapy and Psychosomatics, Oberhausen, Germany (GRID:grid.6190.e) 
13  Heidelberg University, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373) 
Pages
49
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2774363661
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.